JS
BTTX

Jeffrey Smith’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Jeffrey Smith’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300,000
Closed -$2.99M – 147
2021
Q3 		$2.99M Buy
+300,000
New +$2.98M 0.05% 49

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jeffrey Smith's BTTX Position: Q4 2021 in Review

Jeffrey Smith sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q4 2021, closing a stake of 300,000 shares — an estimated $2.99M sold.

Jeffrey Smith first reported a position in BTTX in Q3 2021 and held it in 1 quarter. The position peaked at $2.99M in Q3 2021. 20 funds tracked by Wall St. Rank hold BTTX as of Q4 2021.

  • Jeffrey Smith reported no remaining Better Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jeffrey Smith sold 300,000 Better Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.99M.
  • Jeffrey Smith first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jeffrey Smith's Better Therapeutics, Inc. Common Stock position peaked at $2.99M in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Starboard Value's 13F filing for Q4 2021, filed 14 Feb 2022.